[1]张佳佳,李 庆,王 同.中性粒细胞CD64指数指导慢性阻塞性肺疾病急性加重期抗生素应用的探讨[J].医学信息,2019,(07):78-81.[doi:10.3969/j.issn.1006-1959.2019.07.023]
 ZHANG Jia-jia,LI Qing,WANG Tong.The Application of Neutrophil CD64 Index in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease[J].Medical Information,2019,(07):78-81.[doi:10.3969/j.issn.1006-1959.2019.07.023]
点击复制

中性粒细胞CD64指数指导慢性阻塞性肺疾病急性加重期抗生素应用的探讨()
分享到:

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
期数:
2019年07期
页码:
78-81
栏目:
论著
出版日期:
2019-04-01

文章信息/Info

Title:
The Application of Neutrophil CD64 Index in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease
文章编号:
1006-1959(2019)07-0078-04
作者:
张佳佳1李 庆2王 同1
(1.安徽医科大学第二附属医院全科医学科,安徽 合肥 230601;2.中国科技大学第一附属医院中心实验室,安徽 合肥 230001)
Author(s):
ZHANG Jia-jia1LI Qing2WANG Tong1
(1.Department of General Medicine,the Second Affiliated Hospital of Anhui Medical University, Hefei 230601,Anhui,China;2.Central Laboratory,the First Affiliated Hospital of University of Science and Technology of China,Hefei 230001,Anhui,China)
关键词:
慢性阻塞性肺疾病急性加重期CD64指数抗生素
Keywords:
Chronic obstructive pulmonary diseaseAcute exacerbationCD64 indexAntibiotics
分类号:
R563
DOI:
10.3969/j.issn.1006-1959.2019.07.023
文献标志码:
A
摘要:
目的 研究CD64指数在减少慢性阻塞性肺疾病急性加重期(AECOPD)患者抗生素应用中的意义。方法 选取2017年1月~10月入住我院的120例AECOPD患者,随机分为对照组和实验组,各60例。对照组根据2016年GOLD指南使用抗生素,实验组根据入院2 h内CD64指数水平来决定是否使用抗生素,在第4天、第8天复测CD64指数水平,若第8天CD64指数≤3,则停用抗生素,相反则继续使用抗生素。比较两组不同时间CD64指数、出院时相关指标(临床有效率、抗生素使用时间、住院时间、平均抗生素花费)、出院后1年内相关指标包括:至下次急性加重时间、随访1年内急性加重次数、住院次数及第一秒用力呼气容积(FEV1)变化。结果 治疗后第4天和第8天,实验组CD64指数水平分别为(1.84±0.65)、(0.86±0.05),对照组CD64指数水平分别为(2.52±0.30)、(1.45±0.03)均较入院时的(3.47±1.00)、(3.04±1.12)降低,且实验组CD64指数在治疗后第4天和第8天均低于对照组,差异有统计学意义(P<0.05);②实验组抗生素使用时间、住院时间、平均抗生素花费均少于对照组,差异有统计学意义(P<0.05);两组的临床有效率、至下次急性加重时间、随访1年内急性加重次数、住院次数及FEV1变化比较,差异无统计学意义(P>0.05)。结论 CD64指数可有助于决定AECOPD患者是否使用抗生素,对AECOPD患者抗生素的使用有重要的指导意义
Abstract:
Objective To study the significance of CD64 index in reducing antibiotics in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Methods A total of 120 AECOPD patients admitted to our hospital from January to October 2017 were randomly divided into control group and experimental group, 60 cases each. The control group used antibiotics according to the 2016 GOLD guidelines. The experimental group decided whether to use antibiotics according to the CD64 index level within 2 hours after admission. The CD64 index level was retested on the 4th and 8th days. If the CD64 index was ≤3 on the 8th day, Stop using antibiotics and instead continue to use antibiotics. The CD64 index and discharge-related indicators (clinical efficacy, antibiotic use time, hospitalization time, and average antibiotic cost) were compared between the two groups. The relevant indicators within 1 year after discharge included: the time of the next acute exacerbation, and the number of acute exacerbations within 1 year of follow-up. The number of hospitalizations and the forced expiratory volume (FEV1) in the first second were changed. Results On the 4th day and the 8th day after treatment, the CD64 index levels of the experimental group were (1.84±0.65) and (0.86±0.05), respectively. The CD64 index levels of the control group were (2.52±0.30) and (1.45±0.03), respectively. At the time of admission, (3.47±1.00) and (3.04±1.12) were decreased, and the CD64 index of the experimental group was lower than that of the control group on the 4th and 8th day after treatment, the difference was statistically significant (P<0.05);②Experiment The time of antibiotic use, hospitalization time and average antibiotic cost were lower than the control group, the difference was statistically significant (P<0.05); the clinical effective rate of the two groups, the time of the next acute exacerbation, the number of acute exacerbations within 1 year of follow-up, hospitalization,there was no significant difference in the number of times and changes in FEV1(P>0.05). Conclusion The CD64 index can help determine whether AECOPD patients use antibiotics, which has important guiding significance for the use of antibiotics in AECOPD patients.

参考文献/References:


[1]慢性阻塞性肺疾病急性加重(AECOPD)诊治专家组.慢性阻塞性肺疾病急性加重(AECOPD)诊治中国专家共识(2017年更新版)[J].国际呼吸杂志,2017,37(14):1041-1057.
[2]庞红燕,杨汀,王辰.2016 年更新版 GOLD 慢性阻塞性肺疾病诊断、治疗和预防的全球策略简介[J].中国医学前沿杂志:电子版,2016,8(7):28-32.
[3]Perlat Kapisyzi, Albania, Eduardo A,et al. Global Initiative for Chronic Obstructive Lung Disease (GOLD):Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease(2017 REPORT)[EB/OL].http://www.goldcopd.org.2016-11-10.
[4]Lozano R,Naghavi M,Foreman K,et al.Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010:a systematic analysis for the Global Burden of Disease Study 2010[J].Lancet,2012,380(9859):2095-2128.
[5]Van der Does Y,Rood PP,Haagsma JA,et al.Procalcitonin-guided therapy for the initiation of antibiotics in the ED:a systematic review[J].Am J Emerg Med,2016,34(7):1286-1293.
[6]De Jong E,Van Oers JA,Beishuizen A,et al.Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients:a randomised,controlled, open-label trial[J].Lancet Infect Dis,2016,16(7):819-827.
[7]Schuetz P,Wirz Y,Sager R,et al.Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections[J].Cochrane Database Syst Rev,2017(10):CD007498.
[8]Falsey AR,Becker Kl,Swinburne AJ,et al.Utility of serum procalcitonin values in patients with acute exacerbations of chronic obstructive pulmonary disease: a cautionary note[J].Int J Chron Obstruct Pulmon Dis,2012(7):127-135.
[9]Yang AP,Liu J,Yue LH,et al.Neutrophil CD64 combined with PCT,CRP and WBC improves the sensitivity for the early diagnosis of neonatal sepsis[J].Clin Chem Lab Med,2016,54(2):345-351.
[10]Kipfmueller F,Schneider J,Prusseit J,et al.Role of neutrophil CD64 index as a screening marker for late-onset sepsis in very low birth weight infants[J].PLoS one 2015,10(4):e0124634.
[11]Dai J,Jiang W,Min Z,et al.Neutrophil CD64 as a diagnostic marker for neonatal sepsis: Meta-analysis[J].Adv Clin Exp Med,2017,26(2):327-332.
[12]Fontela PS,O'Donnell S,Papenburg J.Can biomarkers improve the rational use of antibiotics?[J]Curr Opin Infect Dis,2018,31(4):347-352.
[13]García-Salido A,Serrano-González A,Casado-Flores J,et al.CD64 on monocytes and granulocytes in severe acute bronchiolitis:Pilot studyon its usefulness as a bacterial infection biomarker[J].J Leukoc Biol,2018,103(5):965-971.
[14]de Jong E,de Lange DW,Beishuizen A,et al.Neutrophil CD64 expression as a longitudinal biomarker for severe disease and acute infection in critically ill patients[J].Int J Lab Hematol, 2016,38(5):576-84.
[15]Burgos J,Los-Arcos I,Alvarez de la Sierra D,et al.Determination of neutrophil CD64 expression as a prognostic biomarker in patients with community-acquired pneumonia[J].Eur J Clin Microbiol Infect Dis,2016,35(9):1411-1416.
[16]陈雪礼,李观华,汤金萍,等.流式细胞术检测中性粒细胞CD64 在感染性疾病中的诊断价值[J].国际检验医学杂志,2013,34(22):2999-3000.
[17]Qian W,Huang GZ.Neutrophil CD64 as a Marker of Bacterial Infection in Acute Exacerbations of Chronic Obstructive Pulmonary Disease[J].Immunol Invest,2016,45(6):490-503.
[18]Xu N,Chen J,Chang X,et al.nCD64 index as a prognostic biomarker for mortality in acute exacerbation of chronic obstructive pulmonary disease[J].Ann Saudi Med,2016,36(1):37-41.
[19]Hsu KH,Chan MC,Wang JM,et al.Comparison of Fc gamma receptor expression on neutrophils with procalcitonin for the diagnosis of sepsis in critically Hi patients[J].Respirol,2011,16:152-160.
[20]苏密龙,苏智军,余雪平,等.流式细胞术检测单核细胞、中性粒细胞CD64 临床价值研究[J].中国免疫学杂志,2013(29):1072-1076.

相似文献/References:

[1]钟雪梅,李 黎,米热班·热夏提,等.α1-抗胰蛋白酶与维吾尔族慢性阻塞性肺疾病的相关性分析[J].医学信息,2018,(02):67.[doi:10.3969/j.issn.1006-1959.2018.02.023]
 ZHONG Xue-mei,LI Li,Mirban·rixat,et al.Correlation Analysis of α1-antitrypsin and Uygur Chronic Obstructive Pulmonary Disease[J].Medical Information,2018,(07):67.[doi:10.3969/j.issn.1006-1959.2018.02.023]
[2]陈文福.噻托溴铵治疗稳定期慢性阻塞性肺疾病的临床疗效分析[J].医学信息,2018,(02):124.[doi:10.3969/j.issn.1006-1959.2018.02.045]
 CHEN Wen-fu.Clinical Analysis of Tiotropium Bromide in the Treatment of Stable Chronic Obstructive Pulmonary Disease[J].Medical Information,2018,(07):124.[doi:10.3969/j.issn.1006-1959.2018.02.045]
[3]吴仲东.无创机械通气用于COPD合并呼吸衰竭的疗效分析[J].医学信息,2018,(04):106.[doi:10.3969/j.issn.1006-1959.2018.04.036]
 WU Zhong-dong.Clinical Analysis of Noninvasive Mechanical Ventilation in Patients with COPD Complicated with Respiratory Failure[J].Medical Information,2018,(07):106.[doi:10.3969/j.issn.1006-1959.2018.04.036]
[4]龙有珠.氨茶碱联合呼吸功能训练治疗慢性阻塞性肺疾病的疗效分析[J].医学信息,2018,(04):127.[doi:10.3969/j.issn.1006-1959.2018.04.045]
 LONG You-zhu.Effect of Aminophylline Combined with Respiratory Function Training on Chronic Obstructive Pulmonary Disease[J].Medical Information,2018,(07):127.[doi:10.3969/j.issn.1006-1959.2018.04.045]
[5]皮鑫鑫,邓 革.临床药师对1例院内感染患者的病例分析[J].医学信息,2018,(04):188.[doi:10.3969/j.issn.1006-1959.2018.04.072]
[6]马建娟.布地奈德联合异丙托溴铵雾化治疗COPD 急性加重期的效果评价[J].医学信息,2018,(07):141.[doi:10.3969/j.issn.1006-1959.2018.07.048]
 MA Jian-juan.Efficacy Evaluation of Budesonide Combined with Ipratropium Bromide in Treatment of Acute Exacerbation of COPD[J].Medical Information,2018,(07):141.[doi:10.3969/j.issn.1006-1959.2018.07.048]
[7]罗 倩.COPD加重期患者肺功能、血气指标及 炎症指标的变化分析[J].医学信息,2018,(09):114.[doi:10.3969/j.issn.1006-1959.2018.09.034]
 LUO Qian.Changes of Pulmonary Function,Blood Gas and Inflammation in Patients with COPD Exacerbation[J].Medical Information,2018,(07):114.[doi:10.3969/j.issn.1006-1959.2018.09.034]
[8]赵志国.有创-无创序贯通气疗法治疗慢性阻塞性肺疾病 引发的严重呼吸衰竭的临床研究[J].医学信息,2018,(11):110.[doi:10.3969/j.issn.1006-1959.2018.11.034]
 ZHAO Zhi-guo.Clinical Study of Invasive Non-invasive Sequential Ventilation in Treatment of Severe Respiratory Failure Caused by Chronic Obstructive Pulmonary Disease[J].Medical Information,2018,(07):110.[doi:10.3969/j.issn.1006-1959.2018.11.034]
[9]金彦青.NPPV治疗慢性阻塞性肺疾病合并 重症呼吸衰竭的临床疗效观察[J].医学信息,2018,(14):113.[doi:10.3969/j.issn.1006-1959.2018.14.033]
 JIN Yan-qing.Clinical Efficacy of NPPV in the Treatment of Chronic Obstructive Pulmonary Disease with Severe Respiratory Failure[J].Medical Information,2018,(07):113.[doi:10.3969/j.issn.1006-1959.2018.14.033]
[10]张 林,白 俐.扶正化瘀胶囊对慢性阻塞性肺疾病患者炎性因子及 MMP-9、TIMP-1的影响[J].医学信息,2018,(14):152.[doi:10.3969/j.issn.1006-1959.2018.14.047]
 ZHANG Lin,BAI Li.Effect of Fuzheng Huayu Capsule on Inflammatory Factors,MMP-9 and TIMP-1 in Patients with Chronic Obstructive Pulmonary Disease[J].Medical Information,2018,(07):152.[doi:10.3969/j.issn.1006-1959.2018.14.047]

更新日期/Last Update: 2019-04-01